Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Equity

v3.22.2.2
Consolidated Statements of Equity - USD ($)
Total
Class B Common Stock
Series A, Internalization
Common Stock, Internalization
Class B Common Stock, Internalization
Series A Cumulative Redeemable Preferred Stock
Series A Cumulative Redeemable Preferred Stock
Series A, Internalization
Common Stock
Common Stock
Class B Common Stock
Common Stock
Common Stock, Internalization
Common Stock
Class B Common Stock, Internalization
Additional Paid-in Capital
Additional Paid-in Capital
Series A, Internalization
Additional Paid-in Capital
Common Stock, Internalization
Additional Paid-in Capital
Class B Common Stock, Internalization
Retained Deficit
Non-controlling Interest
Beginning balance at Dec. 31, 2020 $ 149,399,827         $ 125,270,350   $ 13,652 $ 0     $ 339,742,380       $ (315,626,555) $ 0
Beginning balance (in shares) at Dec. 31, 2020               13,651,521 0                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                  
Net income (loss) (2,346,883)                             (9,122,746) 6,775,863
Series A preferred stock dividends ($0.4609375 per depositary share) (7,007,474)                     (7,007,474)          
Common Stock dividends (2,106,682)                     (2,106,682)          
Reinvestment of dividends paid to common stockholders (in shares)               58,033                  
Reinvestment of dividends paid to common stockholders 307,414             $ 57       307,357          
Crimson cash dividends on Class A-1 units (1,446,901)                               (1,446,901)
Crimson Class A-2 Units dividends payment in kind (610,353)                               (610,353)
Stock-based compensation (in shares)               3,399                  
Common stock issued under director's compensation plan 22,500             $ 3       22,497          
Stock issued, internalization transaction (in shares)                   1,153,846 683,761            
Stock issued, value, internalization transaction     $ 4,245,112 $ 7,096,153 $ 3,288,890   $ 4,255,325     $ 1,154 $ 684   $ (10,213) $ 7,094,999 $ 3,288,206    
Common stock issued under director's compensation plan (in shares)               3,399                  
Equity attributable to non-controlling interest 116,816,115                               116,816,115
Ending balance at Sep. 30, 2021 267,657,718         129,525,675   $ 14,866 $ 684     341,331,070       (324,749,301) 121,534,724
Ending balance (in shares) at Sep. 30, 2021               14,866,799 683,761                
Beginning balance at Jun. 30, 2021 250,882,083         125,270,350   $ 13,673 $ 0     333,890,658       (327,513,587) 119,220,989
Beginning balance (in shares) at Jun. 30, 2021               13,673,326 0                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                  
Net income (loss) 5,919,971                             2,764,286 3,155,685
Series A preferred stock dividends ($0.4609375 per depositary share) (2,388,130)                     (2,388,130)          
Common Stock dividends (741,530)                     (741,530)          
Reinvestment of dividends paid to common stockholders (in shares)               36,228                  
Reinvestment of dividends paid to common stockholders 174,619             $ 36       174,583          
Crimson cash dividends on Class A-1 units (841,950)                               (841,950)
Crimson Class A-2 Units dividends payment in kind (204,353)                               (204,353)
Stock-based compensation (in shares)               3,399                  
Common stock issued under director's compensation plan 22,500             $ 3       22,497          
Stock issued, internalization transaction (in shares)                   1,153,846 683,761            
Stock issued, value, internalization transaction     4,245,112 7,096,153 3,288,890   $ 4,255,325     $ 1,154 $ 684   $ (10,213) $ 7,094,999 $ 3,288,206    
Common stock issued under director's compensation plan (in shares)               3,399                  
Equity attributable to non-controlling interest 204,353                               204,353
Ending balance at Sep. 30, 2021 267,657,718         129,525,675   $ 14,866 $ 684     341,331,070       (324,749,301) 121,534,724
Ending balance (in shares) at Sep. 30, 2021               14,866,799 683,761                
Beginning balance at Dec. 31, 2021 263,631,523         129,525,675   $ 14,893 $ 684     338,302,735       (327,157,636) 122,945,172
Beginning balance (in shares) at Dec. 31, 2021   683,761           14,893,184 683,761                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                  
Net income (loss) (8,966,821)                             (12,594,834) 3,628,013
Series A preferred stock dividends ($0.4609375 per depositary share) (7,164,390)                     (7,164,390)          
Common Stock dividends (2,245,733)                     (2,245,733)          
Reinvestment of dividends paid to common stockholders (in shares)               221,362                  
Reinvestment of dividends paid to common stockholders 601,184             $ 221       600,963          
Common Stock, accrued dividend equivalent (34,145)                     (34,145)          
Crimson cash dividends on Class A-1 units (2,427,636)                               (2,427,636)
Crimson Class A-2 Units dividends payment in kind 0                                
Stock-based compensation (in shares)               62,365                  
Stock-based compensation 384,383             $ 63       336,619       47,701  
Stock issued, value, internalization transaction     $ 0 $ 0 $ 0                        
Common stock issued under director's compensation plan (in shares)               62,365                  
Ending balance at Sep. 30, 2022 243,778,365         129,525,675   $ 15,177 $ 684     329,796,049       (339,752,470) 124,193,250
Ending balance (in shares) at Sep. 30, 2022   683,761           15,176,911 683,761                
Beginning balance at Jun. 30, 2022 262,833,595         129,525,675   $ 15,060 $ 684     332,588,181       (323,649,718) 124,353,713
Beginning balance (in shares) at Jun. 30, 2022               15,060,857 683,761                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                  
Net income (loss) (15,501,704)                             (16,102,752) 601,048
Series A preferred stock dividends ($0.4609375 per depositary share) (2,388,130)                     (2,388,130)          
Common Stock dividends (753,043)                     (753,043)          
Reinvestment of dividends paid to common stockholders (in shares)               84,606                  
Reinvestment of dividends paid to common stockholders 197,980             $ 85       197,895          
Common Stock, accrued dividend equivalent (34,145)                     (34,145)          
Crimson cash dividends on Class A-1 units (809,212)                               (809,212)
Stock-based compensation (in shares)               31,448                  
Stock-based compensation 233,024             $ 32       185,291         47,701
Common stock issued under director's compensation plan (in shares)               31,448                  
Ending balance at Sep. 30, 2022 $ 243,778,365         $ 129,525,675   $ 15,177 $ 684     $ 329,796,049       $ (339,752,470) $ 124,193,250
Ending balance (in shares) at Sep. 30, 2022   683,761           15,176,911 683,761